Celgene

An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
  • The New England journal of medicine
  • 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (July 13, 2017;377:122-31). The authors’ disclosure… (More)
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who… (More)
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface… (More)
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and… (More)
Is this relevant?
Review
2010
Review
2010
Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-myeloma properties including immune… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2004
Review
2004
Celgene, in collaboration with the National Cancer Institute, is developing CC-5013, the lead compound in a series of thalidomide… (More)
Is this relevant?